Lantern Pharma annual free cash flow
2021
2022
2023
2024
2025
Lantern Pharma reported −$15.7M in free cash flow for fiscal 2025, an increase of $2.1M from the previous fiscal year.
View full Lantern Pharma company overview| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$15.7M | $2.1M | — | — |
| 2024 | 2024-12-31 | −$17.8M | −$3.5M | — | — |
| 2023 | 2023-12-31 | −$14.4M | −$1.6M | — | — |
| 2022 | 2022-12-31 | −$12.8M | −$2.2M | — | — |
| 2021 | 2021-12-31 | −$10.6M | — | — | — |
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | −$2.8M | $1.2M | — | — |
| Q3 2025 | 2025-09-30 | −$4.6M | $1.0M | — | — |
| Q2 2025 | 2025-06-30 | −$3.9M | $1.3M | — | — |
| Q1 2025 | 2025-03-31 | −$4.4M | −$1.3M | — | — |
| Q4 2024 | 2024-12-31 | −$4.0M | −$584,439 | — | — |
| Q3 2024 | 2024-09-30 | −$5.6M | −$2.0M | — | — |
| Q2 2024 | 2024-06-30 | −$5.2M | −$1.6M | — | — |
| Q1 2024 | 2024-03-31 | −$3.1M | $695,292 | — | — |
| Q4 2023 | 2023-12-31 | −$3.4M | $654,545 | — | — |
| Q3 2023 | 2023-09-30 | −$3.6M | $1.1M | — | — |
| Q2 2023 | 2023-06-30 | −$3.6M | — | — | — |
| Q1 2023 | 2023-03-31 | −$3.8M | — | — | — |
| Q3 2022 | 2022-09-30 | −$4.0M | — | — | — |
| Q3 2021 | 2021-09-30 | −$4.7M | — | — | — |
Lantern Pharma's latest reported quarter, Q4 2025, generated −$2.8M in free cash flow, an increase of $1.2M year over year.
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Lantern Pharma filings at SEC.gov ↗